Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,027.30 +2.30 (+0.22%)

Streaming Delayed Price Updated: 10:28 AM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

99 100 Next >

Top S&P500 movers in Friday's session ↗

November 28, 2025

Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Via Chartmill

These S&P500 stocks are moving in today's session ↗

November 28, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.

Via Chartmill

Beyond the Giants: Gauging Emerging Large-Cap Leadership Amidst Broadening Market Dynamics

November 28, 2025

The financial markets in late 2025 are signaling a significant, albeit cautious, shift away from the concentrated leadership that has defined much of the past two years. For an extended period, market...

Via MarketMinute

Eli Lilly Unusual Options Activity ↗

November 28, 2025

Via Benzinga

Gapping S&P500 stocks in Friday's session ↗

November 28, 2025

Curious about the S&P500 stocks that are gapping on Friday? Explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Is Johnson & Johnson Stock Outperforming the S&P 500?

November 28, 2025

Johnson & Johnson has outpaced the S&P 500 over the past year, and analysts remain optimistic about the healthcare stock's growth potential ahead.

Via Barchart.com

Topics Stocks

Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 ↗

November 27, 2025

The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.

Via The Motley Fool

Eli Lilly’s Stock Price Has Fattened Up Like a Thanksgiving Turkey. Time to (Options) Collar That Green!

November 27, 2025

As Eli Lilly makes history by joining the $1 trillion club, here’s how you can position for its next move.

Via Barchart.com

Prediction: This Growth Stock Could Hit a $2 Trillion Valuation by 2031 ↗

November 27, 2025

It's not only tech companies that can get to that market valuation.

Via The Motley Fool

JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets ↗

November 26, 2025

JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.

Via Stocktwits

Topics Economy Government

Stock Split Watch: Is Eli Lilly Next? ↗

November 26, 2025

The stock recently reached beyond $1,000.

Via The Motley Fool

U.S. Stocks Extend Winning Streak as Wall Street Bets on Dovish Fed Pivot

November 26, 2025

New York, NY – November 26, 2025 – U.S. stock markets are surging, with Wall Street poised to extend a remarkable winning streak as investors enthusiastically price in aggressive interest rate cuts by...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Is AbbVie Stock Outperforming the Nasdaq?

November 26, 2025

AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

Via Barchart.com

Topics Stocks

Could AI Infrastructure Spending Be the Next Gold Rush for Investors? ↗

November 26, 2025

Companies and investors see AI as a game-changing technology.

Via The Motley Fool

Topics Artificial Intelligence

Did Pfizer Just Say "Checkmate" to Novo Nordisk? ↗

November 26, 2025

The weight loss drug market may approach almost $100 billion by the end of the decade.

Via The Motley Fool

Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗

November 25, 2025

Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.

Via Stocktwits

Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks

November 25, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Should You Buy the Massive Dip in Novo Nordisk Stock?

November 25, 2025

Novo’s failed Alzheimer’s bet sparked a sharp selloff, leaving investors debating whether this bruising dip is a bargain or not.

Via Barchart.com

Here's Why Novo Nordisk Stock Popped Today ↗

November 25, 2025

Good news from a GLP-1 receptor agonist clinical trial hit the market today.

Via The Motley Fool

The Great Divide: Is the Market Offering a Dip or Signalling a Bear?

November 25, 2025

As November 25, 2025, unfolds, financial markets find themselves at a critical juncture, gripped by a pervasive debate that pits optimists against skeptics: are current market pullbacks merely a "Buy...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Is UnitedHealth Group Stock Underperforming the Nasdaq?

November 25, 2025

Though UnitedHealth Group has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Via Barchart.com

Topics Stocks

A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling ↗

November 25, 2025

Via MarketBeat

How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?

November 25, 2025

Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.

Via Barchart.com

Topics ETFs

This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000? ↗

November 24, 2025

The rapidly expanding market for GLP-1 drugs has added massively to Eli Lilly's market cap.

Via The Motley Fool

Topics Government World Trade

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk ↗

November 24, 2025

Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.

Via Benzinga

Topics ETFs

US Stock Market Navigates AI Euphoria and Rate Cut Hopes Amidst Mounting Volatility

November 24, 2025

The US stock market as of late November 2025 presents a nuanced landscape of resilience and apprehension. While major indices have enjoyed robust year-to-date gains, largely propelled by the relentless...

Via MarketMinute

Topics Artificial Intelligence Economy Electric Vehicles

Novo Nordisk Shares Plunge as Alzheimer's Drug Trial Fails to Meet Primary Endpoint

November 24, 2025

Copenhagen, Denmark – November 24, 2025 – Novo Nordisk's (CPH: NOVO B) stock experienced a significant and immediate downturn today, plummeting by over 10% in early trading, following the announcement...

Via MarketMinute

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

Via Investor Brand Network

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

From BioMedWire

Via GlobeNewswire

Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps ↗

November 24, 2025

Eli Lilly fell while Biogen jumped.

Via Investor's Business Daily

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Eli Lilly (NY:LLY)

All News about Eli Lilly

Starting at $3.75/week.

Subscribe Today